Gene Therapy in Corneal Transplantation

References

• 2011–2012 Year in Review: Focused on Restoring Sight Worldwide. Eye Bank Association of America 2012;1–13. Available at: http://issuu.com/moiremarketing/docs/ebaa-2011-12yir-final?e=1631814/2738036
   Google Scholar
• Thompson RW Jr, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003;110:1396–1402
   PubMed Web of Science ®Google Scholar
• Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol 1990;48:191–226
   PubMedGoogle Scholar
• Williams KA, Lowe M, Bartlett C, et al. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 2008;86:1720–1724
   PubMed Web of Science ®Google Scholar
• Guilbert E, Bullet J, Sandali O, et al. Long-term rejection incidence and reversibility after penetrating and lamellar keratoplasty. Am J Ophthalmol 2013;155:560–569
   PubMed Web of Science ®Google Scholar
• Streilein JW, Yamada J, Dana MR, et al. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc 1999;31:1472–1475
   PubMed Web of Science ®Google Scholar
• Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981;99:599–604
   PubMedGoogle Scholar
• Port FK, Dykstra DM, Merion RM, et al. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005;5:843–849
   PubMed Web of Science ®Google Scholar
• Hamrah P, Mantopoulos, D, Akhtar, J, Djalilian, AR. Immunologically high-risk penetrating keratoplasty. In: Cornea, 3rd ed. Krachmer J, Mannis, MJ, Jolland, EJ, eds. St. Louis: Mosby, 2010. pp 1495–1510
   Google Scholar
• Ling S, Lin H, Xiang D, et al. Clinical and experimental research of corneal lymphangiogenesis after keratoplasty. Ophthalmologica 2008;222:308–316
   PubMedGoogle Scholar
• Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45:2666–2673
   PubMed Web of Science ®Google Scholar
• Bachmann BO, Luetjen-Drecoll E, Bock F, et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 2009;93:1075–1080
   PubMed Web of Science ®Google Scholar
• Hos D, Bock F, Dietrich T, et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261,991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 2008;49:1836–1842
   PubMedGoogle Scholar
• Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010;117:1300–1305
   PubMed Web of Science ®Google Scholar
• Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996;37:2485–2494
   PubMed Web of Science ®Google Scholar
• Dana MR. Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin Ophthalmol 2006;21:19–22
   PubMedGoogle Scholar
• Michael Edelstein. Gene Therapy Clinical Trials Worldwide; John Wiley and Sons Ltd., 2012. Available at: http://www.abedia.com/wiley/search_results.php?TrialCountry=&RefResults=&CategoryMain=Ocular+diseases&Indication=&Vector=&Genes=&GeneTypes=&Phase=&Status=&FinalApprYear=&Submit=%A0%A0Search%A0%A0
   Google Scholar
• Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012: an update. J Gene Med 2013;15:65–77
   PubMed Web of Science ®Google Scholar
• Nosov M, Wilk M, Morcos M, et al. Role of lentivirus-mediated overexpression of programmed death-ligand 1 on corneal allograft survival. Am J Transplant 2012;12:1313–1322
   PubMed Web of Science ®Google Scholar
• Gong N, Pleyer U, Volk HD, et al. Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther 2007;14:484–490
   PubMed Web of Science ®Google Scholar
• Hippert C, Ibanes S, Serratrice N, et al. Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human explants. PLoS One 2012;7:e35318
   PubMed Web of Science ®Google Scholar
• Carlson EC, Liu CY, Yang X, et al. In vivo gene delivery and visualization of corneal stromal cells using an adenoviral vector and keratocyte-specific promoter. Invest Ophthalmol Vis Sci 2004;45:2194–2200
   PubMedGoogle Scholar
• Chong EM, Dana MR. Graft failure IV. Immunologic mechanisms of corneal transplant rejection. Int Ophthalmol 2008;28:209–222
   PubMedGoogle Scholar
• Streilein JW. Immunobiology and immunopathology of corneal transplantation. Chem Immunol 1999;73:186–206
   PubMedGoogle Scholar
• Yamada J, Streilein JW. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci 1997;38:2833–2843
   PubMedGoogle Scholar
• Hamrah P, Liu Y, Zhang Q, et al. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci 2003;44:581–589
   PubMed Web of Science ®Google Scholar
• Hamrah P, Zhang Q, Liu Y, et al. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci 2002;43:639–646
   PubMed Web of Science ®Google Scholar
• Qazi Y, Turhan, A, Hamrah, P. Trafficking of immune cells in the cornea and ocular surface. In: Advances in Ophthalmology. Rumelt S, ed. Rijeka: InTech, 2012. pp 79–104
   Google Scholar
• Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997;64:1107–1111
   PubMed Web of Science ®Google Scholar
• Stuart PM, Griffith TS, Usui N, et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396–402
   PubMed Web of Science ®Google Scholar
• Liechtenstein T, Dufait I, Bricogne C, et al. PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal. J Clin Cell Immunol 2012;S12:006
   Google Scholar
• Shen L, Jin Y, Freeman GJ, et al. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol 2007;179:3672–3679
   PubMed Web of Science ®Google Scholar
• Yang W, Li H, Chen PW, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009;50:273–280
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Sari D, Boussiotis VA. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 2012;11:4305–4309
   PubMed Web of Science ®Google Scholar
• Jiang L, He H, Yang P, et al. Splenic CD8+ T cells secrete TGF-beta1 to exert suppression in mice with anterior chamber-associated immune deviation. Graefes Arch Clin Exp Ophthalmol 2009;247:87–92
   PubMedGoogle Scholar
• Stein-Streilein J, Streilein JW. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol 2002;21:123–152
   PubMedGoogle Scholar
• Wilbanks GA, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991;146:2610–2617
   PubMed Web of Science ®Google Scholar
• Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. I. F. lymphocyte-induced immune deviation. J Immunol 1977;118:809–814
   PubMed Web of Science ®Google Scholar
• Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. J Immunol 1978;120:689–693
   PubMed Web of Science ®Google Scholar
• Streilein JW. Anterior chamber associated immune deviation: the privilege of immunity in the eye. Surv Ophthalmol 1990;35:67–73
   PubMed Web of Science ®Google Scholar
• Yao YF, Inoue Y, Miyazaki D, et al. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice. Invest Ophthalmol Vis Sci 1997;38:292–300
   PubMedGoogle Scholar
• Forrester JV, Xu H, Kuffova L, et al. Dendritic cell physiology and function in the eye. Immunol Rev 2010;234:282–304
   PubMedGoogle Scholar
• Hamrah P, Liu Y, Zhang Q, et al. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol 2003;121:1132–1140
   PubMedGoogle Scholar
• Liu Y, Hamrah P, Zhang Q, et al. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med 2002;195:259–268
   PubMed Web of Science ®Google Scholar
• Khan A, Fu H, Tan LA, et al. Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition. Eur J Immunol 2012;43:734--746
   Google Scholar
• Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplant 2007;7:2082–2089
   PubMed Web of Science ®Google Scholar
• Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255–258
   PubMed Web of Science ®Google Scholar
• Huq S, Liu Y, Benichou G, et al. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J Immunol 2004;173:4464–4469
   PubMed Web of Science ®Google Scholar
• Boisgerault F, Liu Y, Anosova N, et al. Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants. Transplantation 2009;87:16–23
   PubMedGoogle Scholar
• Sano Y, Ksander BR, Streilein JW. Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T-cell allorecognition. Invest Ophthalmol Vis Sci 2000;41:1422–1431
   PubMed Web of Science ®Google Scholar
• Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation 2007;84:806–813
   PubMedGoogle Scholar
• Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 2000;19:625–643
   PubMedGoogle Scholar
• Yamagami S, Amano S. Role of resident corneal leukocytes and draining cervical lymph nodes in corneal allograft rejection. Cornea 2003;22:S61–65
   Google Scholar
• Sano Y, Streilein JW, Ksander BR. Detection of minor alloantigen-specific cytotoxic T cells after rejection of murine orthotopic corneal allografts: evidence that graft antigens are recognized exclusively via the “indirect pathway”. Transplantation 1999;68:963–970
   PubMedGoogle Scholar
• Yamagami S, Miyazaki D, Ono SJ, et al. Differential chemokine gene expression in corneal transplant rejection. Invest Ophthalmol Vis Sci 1999;40:2892–2897
   PubMed Web of Science ®Google Scholar
• Yamagami S, Hamrah P, Zhang Q, et al. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Mol Vis 2005;11:632–640
   PubMedGoogle Scholar
• Yamagami S, Isobe M, Tsuru T. Characterization of cytokine profiles in corneal allograft with anti-adhesion therapy. Transplantation 2000;69:1655–1659
   PubMedGoogle Scholar
• Hegde S, Niederkorn JY. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Vis Sci 2000;41:3341–3347
   PubMed Web of Science ®Google Scholar
• Yamada J, Ksander BR, Streilein JW. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 2001;42:386–392
   PubMed Web of Science ®Google Scholar
• Hegde S, Beauregard C, Mayhew E, et al. CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation 2005;79:23–31
   PubMed Web of Science ®Google Scholar
• Birnbaum F, Bohringer D, Sokolovska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 2005;79:964–968
   PubMed Web of Science ®Google Scholar
• Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. Eye (Lond) 2009;23:708–714
   PubMedGoogle Scholar
• Yamaguchi T, Hamrah, P. Immunotherapy of ocular surface diseases and graft rejection. In: Copland and Afshari's Principles and Practice of Cornea. Copland R, Afshari, NA, eds. New Delhi: Jaypee Brothers, 2013. pp 580–600
   Google Scholar
• Acar BT, Halili E, Acar S. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol 2013
   PubMedGoogle Scholar
• Petsoglou C, Balaggan KS, Dart JK, et al. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 2013;97:28–32
   PubMed Web of Science ®Google Scholar
• Jeong JH, Chun YS, Kim ES, et al. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection. Cornea 2011;30:1071–1077
   PubMedGoogle Scholar
• Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010;51:2411–2417
   PubMed Web of Science ®Google Scholar
• Zaki AA, Farid SF. Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 2010;88:868–871
   PubMedGoogle Scholar
• Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 2007;33:1991–1993
   PubMed Web of Science ®Google Scholar
• Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577–1579
   PubMed Web of Science ®Google Scholar
• Reinhard T, Mayweg S, Reis A, et al. Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int 2005;18:193–197
   PubMed Web of Science ®Google Scholar
• Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 2008;27:488–493
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001;108:1838–1844
   PubMed Web of Science ®Google Scholar
• Joseph A, Raj D, Shanmuganathan V, et al. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol 2007;91:51–55
   PubMed Web of Science ®Google Scholar
• Sinha R, Jhanji V, Verma K, et al. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1167–1172
   PubMedGoogle Scholar
• Belin MW, Bouchard CS, Frantz S, et al. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96:1144–1150
   PubMed Web of Science ®Google Scholar
• Cosar CB, Laibson PR, Cohen EJ, et al. Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens 2003;29:103–107
   PubMedGoogle Scholar
• Miller K, Huber C, Niederwieser D, et al. Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation 1988;45:651–653
   PubMed Web of Science ®Google Scholar
• Poon A, Constantinou M, Lamoureux E, et al. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol 2008;36:415–421
   PubMed Web of Science ®Google Scholar
• Althaus C, Dagres E, Reinhard T, et al. Cyclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high-performance liquid chromatography-electrospray mass spectrometry. Ger J Ophthalmol 1996;5:189–194
   PubMedGoogle Scholar
• Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 1999;83:1268–1271
   PubMed Web of Science ®Google Scholar
• Reinhard T, Mayweg S, Sokolovska Y, et al. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int 2005;18:703–708
   PubMedGoogle Scholar
• Birnbaum F, Reis A, Bohringer D, et al. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006;81:767–772
   PubMed Web of Science ®Google Scholar
• Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol 2010;150:179–184
   PubMed Web of Science ®Google Scholar
• Ippoliti G, Fronterre A. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1989;21:3133–3134
   PubMed Web of Science ®Google Scholar
• Ippoliti G, Fronterre A. Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1987;19:2579–2580
   PubMed Web of Science ®Google Scholar
• Schmitz K, Hitzer S, Behrens-Baumann W. Immunsuppression durch Kombinationstherapie mit Basiliximab und Ciclosporin bei Hochrisikokeratoplastik. Eine Pilotstudie [Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study]. Ophthalmologe 2002;99:38–45
   PubMedGoogle Scholar
• Birnbaum F, Jehle T, Schwartzkopff J, et al. Basiliximab als Monotherapie nach perforierender Risikokeratoplastik: eine prospektive randomisierte Pilotstudie [Basiliximab following penetrating risk-keratoplasty: a prospective randomized pilot study]. Klin Monbl Augenheilkd 2008;225:62–65
   PubMed Web of Science ®Google Scholar
• Hori J, Joyce NC, Streilein JW. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest Ophthalmol Vis Sci 2000;41:3032–3042
   PubMed Web of Science ®Google Scholar
• Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 2007;92:50–57
   PubMedGoogle Scholar
• Bertelmann E. Genetic manipulation of corneal endothelial cells: transfection and viral transduction. Methods Mol Biol 2009;467:229–239
   PubMedGoogle Scholar
• Hu J, Kovtun A, Tomaszewski A, et al. A new tool for the transfection of corneal endothelial cells: calcium phosphate nanoparticles. Acta Biomater 2012;8:1156–1163
   PubMedGoogle Scholar
• Qazi Y, Stagg B, Singh N, et al. Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 2012;53:2837–2844
   PubMedGoogle Scholar
• Baker AH. Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 2004;84:279–299
   PubMed Web of Science ®Google Scholar
• Surace EM, Auricchio A. Adeno-associated viral vectors for retinal gene transfer. Prog Retin Eye Res 2003;22:705–719
   PubMed Web of Science ®Google Scholar
• Shenk T. Adenoviridae: The viruses and their teplication. In: Fields Virology, 3rd ed. Fields B, Knipe, DM, Howley, PM, eds. Philadelphia: Lippincott-Raven, 1996. pp 2111–2148
   Google Scholar
• Petrie NC, Yao F, Eriksson E. Gene therapy in wound healing. Surg Clin North Am 2003;83:597–616
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320–1323
   PubMed Web of Science ®Google Scholar
• Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997;94:3352–3356
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309–319
   PubMed Web of Science ®Google Scholar
• Qian Y, Leong FL, Kazlauskas A, et al. Ex vivo adenovirus-mediated gene transfer to corneal graft endothelial cells in mice. Invest Ophthalmol Vis Sci 2004;45:2187–2193
   PubMed Web of Science ®Google Scholar
• Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci 1995;36:614–621
   PubMed Web of Science ®Google Scholar
• Mashhour B, Couton D, Perricaudet M, et al. In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther 1994;1:122–126
   PubMed Web of Science ®Google Scholar
• Budenz DL, Bennett J, Alonso L, et al. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci 1995;36:2211–2215
   PubMed Web of Science ®Google Scholar
• Larkin DF, Oral HB, Ring CJ, et al. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996;61:363–370
   PubMed Web of Science ®Google Scholar
• Tsubota K, Inoue H, Ando K, et al. Adenovirus-mediated gene transfer to the ocular surface epithelium. Exp Eye Res 1998;67:531–538
   PubMed Web of Science ®Google Scholar
• Klebe S, Sykes PJ, Coster DJ, et al. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001;71:1214–1220
   PubMed Web of Science ®Google Scholar
• Borras T, Tamm ER, Zigler JS Jr. Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Invest Ophthalmol Vis Sci 1996;37:1282–1293
   PubMed Web of Science ®Google Scholar
• Borras T, Gabelt BT, Klintworth GK, et al. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 2001;3:437–449
   PubMed Web of Science ®Google Scholar
• Oral HB, Larkin DF, Fehervari Z, et al. Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Ther 1997;4:639–647
   PubMed Web of Science ®Google Scholar
• Muzyczka N, and Berns KI. Parvoviridae: The viruses and their replication. In: Fields Virology, 4th ed. Knipe D, Howley PM, eds. Philadelphia: Lippincott Williams and Wilkins, 2001. pp 2327–2360
   Google Scholar
• Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy: a review. Stem Cells Dev 2004;13:133–145
   PubMed Web of Science ®Google Scholar
• Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003;7:839–850
   PubMed Web of Science ®Google Scholar
• Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998;72:309–319
   PubMed Web of Science ®Google Scholar
• Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438–1445
   PubMed Web of Science ®Google Scholar
• Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001;276:20610–20616
   PubMed Web of Science ®Google Scholar
• Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002;76:791–801
   PubMed Web of Science ®Google Scholar
• Mohan RR, Sharma A, Netto MV, et al. Gene therapy in the cornea. Prog Retin Eye Res 2005;24:537–559
   PubMed Web of Science ®Google Scholar
• Mohan RR, Schultz GS, Hong JW, et al. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res 2003;76:373–383
   PubMed Web of Science ®Google Scholar
• Hudde T, Rayner SA, De Alwis M, et al. Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea 2000;19:369–373
   PubMed Web of Science ®Google Scholar
• Tsai ML, Chen SL, Chou PI, et al. Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium. Invest Ophthalmol Vis Sci 2002;43:751–757
   PubMed Web of Science ®Google Scholar
• Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854–11859
   PubMed Web of Science ®Google Scholar
• Sharma A, Ghosh A, Hansen ET, et al. Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Res Bull 2010;81:273–278
   PubMed Web of Science ®Google Scholar
• Duan D, Yue Y, Yan Z, et al. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000;6:595–598
   PubMed Web of Science ®Google Scholar
• Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000;6:599–602
   PubMed Web of Science ®Google Scholar
• Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011;19:293–301
   PubMed Web of Science ®Google Scholar
• Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:463–471
   PubMed Web of Science ®Google Scholar
• Zhong L, Li B, Jayandharan G, et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 2008;381:194–202
   PubMed Web of Science ®Google Scholar
• Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008;105:7827–7832
   PubMed Web of Science ®Google Scholar
• Mohan RR, Tovey JC, Sharma A, et al. Gene therapy in the cornea: 2005-present. Prog Retin Eye Res 2012;31:43–64
   PubMed Web of Science ®Google Scholar
• Clements JE, Zink MC. Molecular biology and pathogenesis of animal lentivirus infections. Clin Microbiol Rev 1996;9:100–117
   PubMed Web of Science ®Google Scholar
• Cullen BR, Greene WC. Functions of the auxiliary gene products of the human immunodeficiency virus type 1. Virology 1990;178:1–5
   PubMedGoogle Scholar
• Maddon PJ, McDougal JS, Clapham PR, et al. HIV infection does not require endocytosis of its receptor, CD4. Cell 1988;54:865–874
   PubMed Web of Science ®Google Scholar
• Maddon PJ, Dalgleish AG, McDougal JS, et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47:333–348
   PubMed Web of Science ®Google Scholar
• McDougal JS, Maddon PJ, Dalgleish AG, et al. The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol 1986;51:703–711
   PubMedGoogle Scholar
• Wang X, Appukuttan B, Ott S, et al. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Ther 2000;7:196–200
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Stephens C, Parsley K, et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 2001;8:1665–1668
   PubMed Web of Science ®Google Scholar
• Takahashi K, Luo T, Saishin Y, et al. Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 2002;13:1305–1316
   PubMed Web of Science ®Google Scholar
• Fuchsluger TA, Jurkunas U, Kazlauskas A, et al. Corneal endothelial cells are protected from apoptosis by gene therapy. Hum Gene Ther 2011;22:549–558
   PubMed Web of Science ®Google Scholar
• Fuchsluger TA, Jurkunas U, Kazlauskas A, et al. Anti-apoptotic gene therapy prolongs survival of corneal endothelial cells during storage. Gene Ther 2011;18:778–787
   PubMed Web of Science ®Google Scholar
• Parker DG, Coster DJ, Brereton HM, et al. Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Experiment Ophthalmol 2010;38:405–413
   PubMedGoogle Scholar
• Contreras-Ruiz L, de la Fuente M, Garcia-Vazquez C, et al. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles. Cornea 2010;29:550–558
   PubMed Web of Science ®Google Scholar
• Rafie F, Javadzadeh Y, Javadzadeh AR, et al. In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye. Curr Eye Res 2010;35:1081–1089
   PubMed Web of Science ®Google Scholar
• Farjo R, Skaggs J, Quiambao AB, et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006;1:e38
   PubMed Web of Science ®Google Scholar
• Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003;44:3562–3569
   PubMed Web of Science ®Google Scholar
• Cai X, Conley SM, Nash Z, et al. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. Faseb J 2010;24:1178–1191
   PubMedGoogle Scholar
• Ding XQ, Quiambao AB, Fitzgerald JB, et al. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One 2009;4:e7410
   PubMed Web of Science ®Google Scholar
• Ziady AG, Gedeon CR, Muhammad O, et al. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 2003;8:948–956
   PubMed Web of Science ®Google Scholar
• Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2013;39:508–519
   PubMed Web of Science ®Google Scholar
• Basaran E, Demirel M, Sirmagul B, et al. Polymeric cyclosporine-A nanoparticles for ocular application. J Biomed Nanotechnol 2011;7:714–723
   PubMed Web of Science ®Google Scholar
• Han Z, Conley SM, Makkia R, et al. Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery. PLoS One 2012;7:e52189
   PubMed Web of Science ®Google Scholar
• Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004;15:1255–1269
   PubMed Web of Science ®Google Scholar
• Qazi Y, Stagg, B, Ambati, BK. Nanoparticles in ophthalmic medicine. International Journal of Green Nanotechnology: Biomedicine 2009;1:B3–B8
   Google Scholar
• Jain A, Gulbake A, Shilpi S, et al. Development of surface-functionalised nanoparticles for FGF2 receptor-based solid tumour targeting. J Microencapsul 2012;29:95–102
   PubMed Web of Science ®Google Scholar
• Lu J, Shi M, Shoichet MS. Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. Bioconjug Chem 2009;20:87–94
   PubMed Web of Science ®Google Scholar
• Kukowska-Latallo JF, Bielinska AU, Johnson J, et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A 1996;93:4897–4902
   PubMed Web of Science ®Google Scholar
• Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J Biomed Mater Res 1996;30:53–65
   PubMed Web of Science ®Google Scholar
• Hudde T, Rayner SA, Comer RM, et al. Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. Gene Ther 1999;6:939–943
   PubMed Web of Science ®Google Scholar
• Tang XL, Sun JF, Wang XY, et al. Blocking neuropilin-2 enhances corneal allograft survival by selectively inhibiting lymphangiogenesis on vascularized beds. Mol Vis 2010;16:2354–2361
   PubMedGoogle Scholar
• Cho YK, Uehara H, Young JR, et al. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci 2012;53:2328–2336
   PubMed Web of Science ®Google Scholar
• Cho YK, Zhang X, Uehara H, et al. Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model. Invest Ophthalmol Vis Sci 2012;53:8458–8471
   PubMedGoogle Scholar
• Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye (Lond) 2003;17:906–911
   PubMed Web of Science ®Google Scholar
• Comer RM, King WJ, Ardjomand N, et al. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci 2002;43:1095–1103
   PubMed Web of Science ®Google Scholar
• Gong N, Pleyer U, Yang J, et al. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med 2006;8:459–467
   PubMed Web of Science ®Google Scholar
• Konig Merediz SA, Zhang EP, Wittig B, et al. Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol 2000;238:701–707
   PubMed Web of Science ®Google Scholar
• Klebe S, Coster DJ, Sykes PJ, et al. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol 2005;175:2219–2226
   PubMed Web of Science ®Google Scholar
• Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001;42:1568–1573
   PubMed Web of Science ®Google Scholar
• Yang JW, Ham DS, Kim HW, et al. Expression of Stat3 and indoleamine 2, 3-dioxygenase in cornea keratocytes as factor of ocular immune privilege. Graefes Arch Clin Exp Ophthalmol 2012;250:25–31
   PubMed Web of Science ®Google Scholar
• Ryu YH, Kim JC. Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor. Invest Ophthalmol Vis Sci 2007;48:4148–4152
   PubMedGoogle Scholar
• Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363–1372
   PubMed Web of Science ®Google Scholar
• Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006;36:690–700
   PubMed Web of Science ®Google Scholar
• Wang X, Wang W, Xu J, et al. Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4(+)CD25(+)Foxp3(+) regulatory T cells. Exp Clin Transplant 2013;11:56–62
   PubMedGoogle Scholar
• Shin HJ, Baker J, Leveson-Gower DB, et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4 + CD25 + Foxp3+ regulatory T cells. Blood 2011;118:2342–2350
   PubMed Web of Science ®Google Scholar
• Yuan XB, Yuan YB, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008;349:241–248
   PubMed Web of Science ®Google Scholar
• Beauregard C, Huq SO, Barabino S, et al. Keratocyte apoptosis and failure of corneal allografts. Transplantation 2006;81:1577–1582
   PubMed Web of Science ®Google Scholar
• Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci 2003;44:3326–3331
   PubMedGoogle Scholar
• Claerhout I, Beele H, Kestelyn P. Graft failure: I. Endothelial cell loss. Int Ophthalmol 2008;28:165–173
   PubMedGoogle Scholar
• Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997;91:443–446
   PubMed Web of Science ®Google Scholar
• Klausner EA, Peer D, Chapman RL, et al. Corneal gene therapy. J Control Release 2007;124:107–133
   PubMed Web of Science ®Google Scholar
• Shiraishi A, Converse RL, Liu CY, et al. Identification of the cornea-specific keratin 12 promoter by in vivo particle-mediated gene transfer. Invest Ophthalmol Vis Sci 1998;39:2554–2561
   PubMed Web of Science ®Google Scholar
• Tong YC, Chang SF, Liu CY, et al. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J Gene Med 2007;9:956–966
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: the eye. Gene Ther 2006;13:1191–1197
   PubMed Web of Science ®Google Scholar
• Williams KA, Coster DJ. Gene therapy for diseases of the cornea: a review. Clin Experiment Ophthalmol 2010;38:93–103
   PubMed Web of Science ®Google Scholar
• Parker DG, Brereton HM, Klebe S, et al. A steroid-inducible promoter for the cornea. Br J Ophthalmol 2009;93:1255–1259
   PubMedGoogle Scholar
• Uehara H, Cho Y, Simonis J, et al. Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). Faseb J 2013;27:76–85
   PubMed Web of Science ®Google Scholar
• Owen LA, Uehara H, Cahoon J, et al. Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One 2012;7:e33576
   PubMed Web of Science ®Google Scholar
• Cho YK, Uehara H, Young JR, et al. Vascular endothelial growth factor receptor 1 morpholino decreases angiogenesis in a murine corneal suture model. Invest Ophthalmol Vis Sci 2012;53:685–692
   PubMedGoogle Scholar
• Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643–650
   PubMed Web of Science ®Google Scholar
• Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4:120ra115
   Web of Science ®Google Scholar
• Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597–1605
   PubMed Web of Science ®Google Scholar
• Vandenberghe LH, Bell P, Maguire AM, et al. AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS One 2013;8:e53463
   Google Scholar
• Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011;3:88ra54
   PubMed Web of Science ®Google Scholar